Identification and validation of a PD-L1-related signature from mass spectrometry in gastric cancer

J Cancer Res Clin Oncol. 2023 Aug;149(9):5871-5884. doi: 10.1007/s00432-022-04529-6. Epub 2023 Jan 2.

Abstract

Background: According to the guidelines, PD-L1 expression is a critical indicator for guiding immunotherapy application. According to certain studies, regardless of PD-L1 expression, immunotherapy could be advantageous for individuals with gastric cancer. Therefore, new scoring systems or biomarkers are required to enhance treatment strategies.

Methods: Mass spectrometry and machine learning were used to search for strongly related PD-L1 genes, and the NMF approach was then used to separate gastric cancer patients into two categories. Differentially expressed genes (DEGs) between the two subtypes identified in this investigation were utilized to develop the UBscore predictive model, which was verified by the Gene Expression Omnibus (GEO) database. Coimmunoprecipitation, protein expression, and natural killing (NK) cell coculture experiments were conducted to validate the findings.

Results: A total of 123 proteins were identified as PD-L1 interactors that are substantially enriched in the proteasome complex at the mRNA level. Using random forest, 30 UPS genes were discovered in the GSE66229 cohort, and ANAPC7 was experimentally verified as one of 123 PD-L1 interactors. Depending on the expression of PD-L1 and ANAPC7, patients were separated into two subgroups with vastly distinct immune infiltration. Low UBscore was related to increased tumor mutation burden (TMB) and microsatellite instability-high (MSI-H). In addition, chemotherapy medications were more effective in individuals with a low UBscore. Finally, we discovered that ANAPC7 might lead to the incidence of immunological escape when cocultured with NK-92 cells.

Conclusion: According to our analysis of the PD-L1-related signature in GC, the UBscore played a crucial role in prognosis and had a strong relationship with TMB, MSI, and chemotherapeutic drug sensitivity. This research lays the groundwork for improving GC patient prognosis and treatment response.

Keywords: Immunotherapy; Machine learning; Mass spectrometry; PD-L1; Tumor microenvironment.

MeSH terms

  • Apc7 Subunit, Anaphase-Promoting Complex-Cyclosome
  • B7-H1 Antigen
  • Biomarkers, Tumor / analysis
  • Biomarkers, Tumor / genetics
  • Humans
  • Mass Spectrometry
  • Microsatellite Instability
  • Prognosis
  • Stomach Neoplasms* / genetics
  • Stomach Neoplasms* / pathology
  • Stomach Neoplasms* / therapy

Substances

  • B7-H1 Antigen
  • Apc7 Subunit, Anaphase-Promoting Complex-Cyclosome
  • Biomarkers, Tumor